Hemispherx Biopharma to Present During the 2014 BIO International Convention June 26

Hemispherx Biopharma to Present During the 2014 BIO International Convention
June 26

PHILADELPHIA, June 25, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc.
(NYSE MKT:HEB) (the "Company" or "Hemispherx"), will present a corporate
update on their Advanced Therapies for the Human Immune System at 9:45 a.m.
Pacific Time on June 26, during the 2014 BIO International Convention at the
San Diego Convention Center.

BIO 2014 is the world's largest, most influential event for the biotechnology
industry, regularly attracting more than 15,000 high-level professionals from
48 states and more than 60 countries. The annual event highlights the latest
advancements in biotechnology.

About BIO

BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and related
organizations across the United States and in more than 30 other nations. BIO
members are involved in the research and development of innovative healthcare,
agricultural, industrial and environmental biotechnology products. BIO also
produces the BIO International Convention, the world's largest gathering of
the biotechnology industry, along with industry-leading investor and
partnering meetings held around the world.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company
engaged in the manufacture and clinical development of new drug entities for
treatment of seriously debilitating disorders. Hemispherx's flagship products
include Alferon N Injection(R) and the experimental therapeutics Ampligen(R)
and Alferon(R) LDO. Ampligen(R) is an experimental RNA nucleic acid being
developed for globally important debilitating diseases and disorders of the
immune system, including Chronic Fatigue Syndrome. Hemispherx's platform
technology includes components for potential treatment of various severely
debilitating and life threatening diseases. Because both Ampligen(R) and
Alferon(R) LDO are experimental in nature, they are not designated safe and
effective by a regulatory authority for general use and are legally available
only through clinical trials. Hemispherx has patents comprising its core
intellectual property estate and a fully commercialized product (Alferon N
Injection(R)), approved for sale in the U.S. and Argentina. The Company's
Alferon(R) N approval in Argentina includes the use of Alferon N Injection(R)
(under the brand name "Naturaferon") for use in any patients who fail, or
become intolerant to recombinant interferon, including patients with chronic
active hepatitis C infection. The Company wholly owns and exclusively operates
a GMP certified manufacturing facility in the United States for commercial
products. For more information please visit www.hemispherx.net.

Disclosure Notice

Information contained in this news release, other than historical information,
should be considered forward-looking and is subject to various risk factors
and uncertainties. For instance, the strategies and operations of Hemispherx
involve risk of competition, changing market conditions, changes in laws and
regulations affecting these industries and numerous other factors discussed in
this release and in the Company's filings with the Securities and Exchange

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Words such as "potential," "potentially," "possible," and similar
expressions are intended to identify forward-looking statements. The inclusion
of forward-looking statements should not be regarded as a representation by
Hemispherx that any of its plans will be achieved. These forward-looking
statements are neither promises nor guarantees of future performance, and are
subject to a variety of risks and uncertainties, many of which are beyond
Hemispherx's control, which could cause actual results to differ materially
from those contemplated in these forward-looking statements. Examples of such
risks and uncertainties include those set forth in the Disclosure Notice,
above, as well as the risks described in Hemispherx's filings with the
Securities and Exchange Commission, including the most recent reports on Forms
10-K, 10-Q and 8-K. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof, and
Hemispherx undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new information,
future events or circumstances or otherwise revise or update this release to
reflect events or circumstances after the date hereof.

CONTACT: For More Information Contact:
         Charles Jones
         CJones & Associates Public Relations
Press spacebar to pause and continue. Press esc to stop.